CD8A and neoplasm: To further explore the mechanism behind TIM-3 decrease in CD8+ TIL, we conducted a similar experiment with intraperitoneal vehicle or FTY720 treatment, a compound inhibiting the recruitment of new lymphocytes into tumor.